Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children
- 1 March 2002
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 29 (6) , 497-502
- https://doi.org/10.1038/sj.bmt.1703406
Abstract
We present a clinical scale method for immunomagnetic separation of CD56+ donor natural killer cells for adoptive immunotherapy of pediatric leukemias after allogeneic transplantation. This time-saving and partially automated procedure employed CD56+ selection followed by CD3+ depletion, resulting in a median purity of 98.6% NK cells and a four-log depletion of T cells. The enriched NK cells demonstrated high cytotoxic activity against K562 target cells and fresh leukemic blasts with low HLA class I expression, which could be further enhanced by IL-2 stimulation. Lysis of NK-insensitive leukemic cells with high HLA class I expression could also be demonstrated via ADCC. Due to the high degree of T cell depletion, alloreactive proliferation in mixed lymphocyte cultures and response to T cell-specific mitogen stimulation was profoundly decreased. Our results suggest that, even in the case of mismatched donors, infusions of donor NK cells with extremely low T cell content may be a promising treatment option for leukemic minimal residual disease after allogeneic transplantation without risk of inducing severe GVHD. Bone Marrow Transplantation (2002) 29, 497–502. doi:10.1038/sj.bmt.1703406Keywords
This publication has 15 references indexed in Scilit:
- In search of the ‘missing self’: MHC molecules and NK cell recognitionPublished by Elsevier ,2003
- Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in childrenBone Marrow Transplantation, 2001
- Donor leukocyte infusions in acute lymphocytic leukemiaBone Marrow Transplantation, 2000
- Transplantation of Megadoses of Purified Haploidentical Stem CellsAnnals of the New York Academy of Sciences, 1999
- Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cellsBone Marrow Transplantation, 1998
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998
- Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.Journal of Clinical Investigation, 1998
- Human NK cells: their ligands, receptors and functionsImmunological Reviews, 1997
- Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derivedCancer Immunology, Immunotherapy, 1995
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987